Prostate Cancer Clinical Trial

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)

Summary

This phase III trial investigates if perflutren lipid microspheres with ultrasound can be used to diagnose prostate cancer non-invasively. Definity (perflutren lipid microspheres) is an ultrasound contrast agent that is typically used for ultrasound bubble studies that involve the heart. Definity appears on ultrasound images as tiny gas-filled microbubbles. These microbubbles are about the size of a red blood cell and do not stay in a patient's body for more than several minutes, where they are excreted from the lungs and exhaled back into the air when breathing. Definity may enhance ultrasound images of the prostate and help doctors identify prostate cancer on ultrasound images.

View Full Description

Full Description

PRIMARY OBJECTIVES:

I. To collect multiparametric ultrasound (mp-US) data on 50 patients > 3 days prior to radical prostatectomy.

II. To correlate the imaging data with whole mount prostatectomy specimens in order to optimize mp-US with a machine learning approach.

OUTLINE:

Patients receive perflutren lipid microspheres intravenously (IV) over 5-6 minutes and undergo ultrasound over 30 minutes. Patients may receive up to 2 additional doses of perflutren lipid microspheres during ultrasound.

After completion of study, patients are followed up for 30 days.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject must be scheduled for radical prostatectomy for treatment of prostate cancer
Subject must be able and willing to give written informed consent for a contrast enhanced ultrasound study of the prostate prior to prostatectomy
Subject must be a male at least 18 years of age when informed consent is obtained

Exclusion Criteria:

Participant in a clinical trial involving an investigational drug within the past 30 days
Patients with known or suspected hypersensitivity to perflutren, PEG, or any other component of Definity
Previous treatment for prostate cancer, including hormone therapy
Clinically unstable, severely ill, or moribund as per treating physician

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

50

Study ID:

NCT05336786

Recruitment Status:

Recruiting

Sponsor:

Thomas Jefferson University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia Pennsylvania, 19107, United States More Info
Flemming Forsberg, PhD
Contact
215-955-4870
[email protected]
Amsterdam University Medical Centers
Amsterdam , , Netherlands More Info
H.P. Beerlage, MD
Contact

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

50

Study ID:

NCT05336786

Recruitment Status:

Recruiting

Sponsor:


Thomas Jefferson University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.